Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study

McInnes, IB, Mease, PJ, Kivitz, AJ et al. (9 more authors) (2020) Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. The Lancet Rheumatology, 2 (4). e227-e235. ISSN 2665-9913

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2020 Elsevier Ltd. This is an author produced version of a paper published in The Lancet Rheumatology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Accepted: 3 February 2020
  • Published (online): 26 March 2020
  • Published: April 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Musculoskeletal Medicine & Imaging (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 06 Feb 2020 15:43
Last Modified: 26 Sep 2020 00:38
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S2665-9913(20)30036-9

Download

Filename: clean AAM.pdf

Licence: CC-BY-NC-ND 4.0

Share / Export

Statistics